LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.
In its latest annual review, the CGT Catapult demonstrates how it is uniquely positioned to deliver critical advances in the cell and gene therapy industry, from driving forward the industry’s productivity for the economy to improving patient outcomes.
AAVantgarde's Stargardt disease and Usher syndrome Ib programmes address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss.
LinkGevity featured in Financial Times 5-part global series on Longevity companies. The article highlights how LinkGevity’s pioneering work on Anti-Necrotic technology is opening new frontiers in medicine, with potential for systemic healthspan regeneration.
A new paper published in the British Journal of Clinical Pharmacology sets out a roadmap for designing the next generation of system-level medicines - drugs that deliver the sweeping system-wide health benefits seen with GLP-1s such as Ozempic and Wegovy, but without their biological trade-offs and side effects.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced it has joined the American Heart Association Center for Health Technology & Innovation’s Innovators’ Network.
Research shows that while 85% of biopharma executives view partnerships as business-critical, around half report failure rates exceeding 60%. Baringa is on a mission to help life sciences organisations get partnering right.
LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.
Last week, the Teesside business community and local guests came together at Wilton Centre, near Redcar, to commemorate the 50th anniversary of the iconic research space, a renowned landmark in Europe’s R&D landscape.
NRG announced the expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.
Coulter Partners completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer.
Medannex Ltd (Edinburgh) announced the presentation of the first clinical data from the ongoing Phase 1b study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.
Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months
A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.
The Oxford Science Park (TOSP), one of Europe’s leading destinations for science and technology companies, today announced the sale of part of its estate to the Ellison Institute of Technology (EIT).
